• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DICE Therapeutics, Inc. - Common Stock (NQ:DICE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about DICE Therapeutics, Inc. - Common Stock

BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
September 01, 2023
Via Investor Brand Network
News headline image
Why These 3 Large Caps Are Bucking the August Slump
August 22, 2023
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023. 
Via MarketBeat
Topics Economy Stocks
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
July 26, 2023
Via Investor Brand Network
Topics Intellectual Property
News headline image
DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
July 10, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE
June 21, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
June 21, 2023
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. 
Via MarketBeat
Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments
June 20, 2023
Via Spotlight Growth
News headline image
DICE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DICE Therapeutics, Inc. Is Fair to Shareholders
June 20, 2023
From Halper Sadeh LLC
Via Business Wire
News headline image
DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
June 13, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 23, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 15, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting
March 01, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Participate at Upcoming Investor Conferences
February 08, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
November 09, 2022
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics to Present at Upcoming Investor Conferences
November 03, 2022
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 17, 2022
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Announces Pricing of Upsized Public Offering of Common Stock
October 12, 2022
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Announces Proposed Public Offering of Common Stock
October 11, 2022
From DICE Therapeutics, Inc.
Via GlobeNewswire
News headline image
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
October 11, 2022
From DICE Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap